These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21902077)

  • 61. At the center of health care policy making: the use of health technology assessment at NICE.
    Stevens AJ; Longson C
    Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
    Chauhan D; Miners AH; Fischer AJ
    Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.
    Gandjour A
    BMC Health Serv Res; 2020 Apr; 20(1):343. PubMed ID: 32321496
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How much should we spend on health care?
    Appleby J
    Surgeon; 2015 Jun; 13(3):121-6. PubMed ID: 25500496
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rationing health care: from needs to markets? The politics of destruction: rationing in the UK health care market.
    Pollock AM
    Health Care Anal; 1995 Nov; 3(4):299-308; discussion 309-14. PubMed ID: 10156208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An assessment of the impact of the NHS Health Technology Assessment Programme.
    Hanney S; Buxton M; Green C; Coulson D; Raftery J
    Health Technol Assess; 2007 Dec; 11(53):iii-iv, ix-xi, 1-180. PubMed ID: 18031652
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rights, responsibilities and NICE: a rejoinder to Harris.
    Claxton K; Culyer AJ
    J Med Ethics; 2007 Aug; 33(8):462-4. PubMed ID: 17664303
    [TBL] [Abstract][Full Text] [Related]  

  • 71. National Institute for Clinical Excellence and its value judgments.
    Rawlins MD; Culyer AJ
    BMJ; 2004 Jul; 329(7459):224-7. PubMed ID: 15271836
    [TBL] [Abstract][Full Text] [Related]  

  • 72. How different are NHS systems across the UK since devolution?
    Hawkes N
    BMJ; 2013 May; 346():f3066. PubMed ID: 23674337
    [No Abstract]   [Full Text] [Related]  

  • 73. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
    Hailey D
    Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Core and comprehensive health care services: 4. Economic issues.
    Wyman M; Feeley J; Brimacombe G; Doucette K
    CMAJ; 1995 May; 152(10):1601-4. PubMed ID: 7743446
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Health care technology in the United Kingdom.
    Spiby J
    Health Policy; 1994; 30(1-3):295-334. PubMed ID: 10139494
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mental health services commissioning and provision: Lessons from the UK?
    Ikkos G; Sugarman P; Bouras N
    Psychiatriki; 2015; 26(3):181-7. PubMed ID: 26480222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.